Revision as of 16:59, 2 March 2021 editBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,621 edits + cite← Previous edit | Revision as of 13:04, 30 March 2021 edit undoRfl0216 (talk | contribs)Extended confirmed users179,129 editsNo edit summaryNext edit → | ||
Line 1: | Line 1: | ||
{{multiple issues| | {{multiple issues| | ||
{{context|date=April 2014}} | {{context|date=April 2014}} | ||
{{ |
{{one source|date=March 2021}} | ||
}} | }} | ||
{{Drugbox | {{Drugbox |
Revision as of 13:04, 30 March 2021
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Clinical data | |
---|---|
Other names | (1S)-1-(diethylamino)propan-2-yl 1-hydroxybi(cyclohexane)-2-carboxylate |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.053.356 |
Chemical and physical data | |
Formula | C20H37NO3 |
Molar mass | 339.520 g·mol |
(verify) |
Rociverine is an antimuscarinic drug.
References
- Toson G, Schiantarelli P, Murmann W (1978). "Rociverine, a new antispasmodic agent with balanced neurotropic and myotropic activity". Arzneimittel-Forschung. 28 (7): 1130–42. PMID 582702.
Drugs for functional gastrointestinal disorders (A03) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drugs for functional bowel disorders |
| ||||||||||||
Belladonna and derivatives (antimuscarinics) |
| ||||||||||||
Propulsives |
This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it. |